Biodesix leaders shared commercial and pipeline updates at the annual qPCR and dPCR Congress
Biodesix announces new data, presented at AMP2017, supporting the analytic validity of automated RNA extraction with the GeneStrat test
Biodesix is making an oral presentation at SITC regarding a testing methodology that may identify primary immunotherapy resistance in patients
Blood-based diagnostic approach to PD-L1 testing that shows concordance with immunohistochemistry; new data presented at EORTC
Biodesix will present posters and an oral presentation of data at SITC 2017 Annual Meeting.
Biodesix commended the Centers for Medicare & Medicaid Services (CMS) for publishing preliminary 2018 rates for clinical diagnostic laboratory tests.
A recent study published in the peer-reviewed journal Managed Care affirms VeriStrat; demonstrates the value of the VeriStrat lung cancer test
Interim study results: Veristrat testing impacts lung cancer treatment in all stages; early stage patients get significantly different treatments after test
Biodesix is presenting two talks on DNA process optimization at the Cancer Genomics Consortium
Peer reviewed journal: VeriStrat test identifies patients with squamous cell lung cancer who are more likely to have improved survival on afatanib (Gilotrif)